Sunzen Biotech Berhad (KLSE:SUNZEN) - Prezzo delle azioni, notizie e analisi

SUNZEN Panoramica delle azioni

SUNZEN analisi fondamentale
Punteggio fiocco di neve
Valutazione	2/6
Crescita futura	0/6
Prestazioni passate	4/6
Salute finanziaria	6/6
Dividendi	0/6

Premi

Negoziato a 78.9% al di sotto della nostra stima del suo valore equo

Gli utili sono cresciuti del 43.5% nell'ultimo anno

Analisi del rischio

Gli azionisti sono stati diluiti nell'ultimo anno

Non ha una capitalizzazione di mercato significativa ( MYR246M )

Sunzen Biotech Berhad Concorrenti

Nova Wellness Group Berhad

KLSE:NOVA

RM 149.8m

Karex Berhad

KLSE:KAREX

RM 948.1m

DXN Holdings Bhd

KLSE:DXN

RM 2.4b

Coreana CosmeticsLtd

KOSDAQ:A027050

₩74.8b

Storia dei prezzi e prestazioni

Riepilogo dei massimi storici, delle variazioni e dei cali di prezzo di tutti i tempi per Sunzen Biotech Berhad
Prezzi storici delle azioni
Prezzo attuale dell'azione	RM 0.32
Massimo di 52 settimane	RM 0.40
Minimo di 52 settimane	RM 0.22
Beta	1.69
1Variazione di 1 mese	-5.97%
Variazione a 3 mesi	-1.56%
Variazione di 1 anno	14.55%
3Variazione a 3 anni	65.79%
Variazione a 5 anni	142.31%
Variazione dall'IPO	68.75%

Notizie e aggiornamenti recenti

Sunzen Biotech Berhad's (KLSE:SUNZEN) Promising Earnings May Rest On Soft Foundations

Nov 07

Sunzen Biotech Berhad's (KLSE:SUNZEN) Shareholders Might Be Looking For Exit

Oct 15

Recent updates

Sunzen Biotech Berhad's (KLSE:SUNZEN) Promising Earnings May Rest On Soft Foundations

Nov 07

Sunzen Biotech Berhad's (KLSE:SUNZEN) Shareholders Might Be Looking For Exit

Oct 15

Sunzen Biotech Berhad's (KLSE:SUNZEN) Returns On Capital Are Heading Higher

Aug 06

If EPS Growth Is Important To You, Sunzen Biotech Berhad (KLSE:SUNZEN) Presents An Opportunity

May 25

Optimistic Investors Push Sunzen Biotech Berhad (KLSE:SUNZEN) Shares Up 27% But Growth Is Lacking

May 24

Sunzen Biotech Berhad (KLSE:SUNZEN) Is Doing The Right Things To Multiply Its Share Price

Apr 22

Sunzen Biotech Berhad (KLSE:SUNZEN) Shareholders Will Want The ROCE Trajectory To Continue

Jan 19

What Sunzen Biotech Berhad's (KLSE:SUNZEN) 27% Share Price Gain Is Not Telling You

Nov 16

Health Check: How Prudently Does Sunzen Biotech Berhad (KLSE:SUNZEN) Use Debt?

Mar 26

Is Sunzen Biotech Berhad (KLSE:SUNZEN) Weighed On By Its Debt Load?

Dec 10

Rendimenti per gli azionisti

	SUNZEN	MY Personal Products	MY Mercato
7D	0%	-0.7%	-0.2%
1Y	14.5%	-16.7%	9.5%

Ritorno vs Industria: SUNZEN ha superato il MY Personal Products che ha restituito -16.7 % nell'ultimo anno.

Rendimento vs Mercato: SUNZEN ha superato il mercato MY che ha restituito 9.5 % nell'ultimo anno.

Volatilità dei prezzi

Is SUNZEN's price volatile compared to industry and market?
SUNZEN volatility
SUNZEN Average Weekly Movement	3.4%
Personal Products Industry Average Movement	4.0%
Market Average Movement	5.0%
10% most volatile stocks in MY Market	10.1%
10% least volatile stocks in MY Market	2.6%

Prezzo delle azioni stabile: SUNZEN non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.

Volatilità nel tempo: La volatilità settimanale ( 3% ) di SUNZEN è rimasta stabile nell'ultimo anno.

Informazioni sull'azienda

Fondato	I dipendenti	AMMINISTRATORE DELEGATO	Sito web
1998	n/a	Yek Teo	www.sunzen.com.my

Sunzen Biotech Berhad si occupa di ricerca e sviluppo biotecnologico, produzione e commercializzazione di integratori alimentari per animali in Malesia, Cina, Singapore e a livello internazionale. Opera attraverso tre segmenti: Salute animale, Salute umana e Finanziamento dei prestiti. L'azienda fornisce macchine veterinarie, prodotti farmaceutici e chimici, prodotti e attrezzature per la salute degli animali, servizi di laboratorio e prodotti di bellezza e cosmetici.

Sunzen Biotech Berhad Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Sunzen Biotech Berhad con la sua capitalizzazione di mercato?
SUNZEN statistiche fondamentali
Capitalizzazione di mercato	RM 245.80m
Guadagni(TTM)	RM 6.03m
Ricavi(TTM)	RM 95.12m

40.8x

Rapporto P/E

2.6x

Rapporto P/S

SUNZEN è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Guadagni e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
SUNZEN Conto economico (TTM)
Ricavi	RM 95.12m
Costo del fatturato	RM 69.57m
Profitto lordo	RM 25.55m
Altre spese	RM 19.53m
Guadagni	RM 6.03m

Ultimi guadagni dichiarati

Jun 30, 2024

Prossima data di guadagno

n/a

Utile per azione (EPS)	0.0077
Margine lordo	26.86%
Margine di profitto netto	6.34%
Rapporto debito/patrimonio netto	4.3%

Come si è comportato SUNZEN nel lungo periodo?

Vedi performance storica e confronto

SUNZEN Panoramica delle azioni

Premi

Analisi del rischio

Sunzen Biotech Berhad Concorrenti

KLSE:NOVA

RM 149.8m

KLSE:KAREX

RM 948.1m

KLSE:DXN

RM 2.4b

KOSDAQ:A027050

₩74.8b

Storia dei prezzi e prestazioni

Notizie e aggiornamenti recenti

Sunzen Biotech Berhad's (KLSE:SUNZEN) Promising Earnings May Rest On Soft Foundations

Sunzen Biotech Berhad, Annual General Meeting, Dec 19, 2024

Sunzen Biotech Berhad, Annual General Meeting, Dec 19, 2024

Sunzen Biotech Berhad's (KLSE:SUNZEN) Shareholders Might Be Looking For Exit

New major risk - Shareholder dilution

Sunzen Biotech Berhad (KLSE:SUNZEN) acquired additional 30% stake in Ecolite Biotech Manufacturing Sdn Bhd from group of sellers for MYR 15 million.

Recent updates

Sunzen Biotech Berhad's (KLSE:SUNZEN) Promising Earnings May Rest On Soft Foundations

Sunzen Biotech Berhad, Annual General Meeting, Dec 19, 2024

Sunzen Biotech Berhad, Annual General Meeting, Dec 19, 2024

Sunzen Biotech Berhad's (KLSE:SUNZEN) Shareholders Might Be Looking For Exit

New major risk - Shareholder dilution

Sunzen Biotech Berhad (KLSE:SUNZEN) acquired additional 30% stake in Ecolite Biotech Manufacturing Sdn Bhd from group of sellers for MYR 15 million.

Sunzen Biotech Berhad's (KLSE:SUNZEN) Returns On Capital Are Heading Higher

Now 22% undervalued

If EPS Growth Is Important To You, Sunzen Biotech Berhad (KLSE:SUNZEN) Presents An Opportunity

Optimistic Investors Push Sunzen Biotech Berhad (KLSE:SUNZEN) Shares Up 27% But Growth Is Lacking

Sunzen Biotech Berhad (KLSE:SUNZEN) Is Doing The Right Things To Multiply Its Share Price

Sunzen Biotech Berhad (KLSE:SUNZEN) Shareholders Will Want The ROCE Trajectory To Continue

Sunzen Biotech Berhad Announces Appointment of Aida Lim Binti Abdullah as Independent and Non Executive Member of Nomination Committee

Third quarter 2023 earnings released: EPS: RM0.002 (vs RM0.001 in 3Q 2022)

Sunzen Biotech Berhad Announces Resignation of Zeenath Begum Binti Mohamed Mastan as Joint Company Secretary

What Sunzen Biotech Berhad's (KLSE:SUNZEN) 27% Share Price Gain Is Not Telling You

Sunzen Biotech Berhad Announces Appointment of Lee Yew Weng as Non Independent and Non Executive Member of Remuneration Committee

Sunzen Biotech Berhad Appoints Lee Yew Weng as Non Independent and Non Executive Member of Nomination Committee

Second quarter 2023 earnings released: EPS: RM0.001 (vs RM0.001 in 2Q 2022)

Sunzen Biotech Berhad Announces the Resignation of Dr. Fong Chan Seng as Independent and Non Executive Director, Member of Remuneration Committee, Chairman of Nomination Committee

First quarter 2023 earnings released: EPS: RM0.002 (vs RM0.001 in 1Q 2022)

Sunzen Biotech Berhad Announces Redesignation of Ching Chee Pun as Executive Chairman

Full year 2022 earnings released: EPS: RM0.005 (vs RM0.001 in FY 2021)

Third quarter 2022 earnings released: EPS: RM0.001 (vs RM0 in 3Q 2021)

Second quarter 2022 earnings released: EPS: RM0.001 (vs RM0 in 2Q 2021)

First quarter 2022 earnings released: EPS: RM0.001 (vs RM0 in 1Q 2021)

Sunzen Biotech Berhad Announces Resignation of Lim Lee Kuan as Company Secretary

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Sunzen Biotech Berhad Announces the Re-Designation of Teo Yek Ming from Group Chief Executive Officer to Group Managing Director

Sunzen Biotech Berhad (KLSE:SUNZEN) completed the acquisition of Finsource Solution Sdn Bhd from Teo Yek Ming, Ching Chee Pun, Lee Ching Yong and Low Chee Yeap.

Health Check: How Prudently Does Sunzen Biotech Berhad (KLSE:SUNZEN) Use Debt?

Full year 2020 earnings released: RM0.025 loss per share (vs RM0.034 loss in FY 2019)

New 90-day high: RM0.22

Sunzen Biotech Berhad (KLSE:SUNZEN) entered into a conditional share sale agreement to acquire Finsource Solution Sdn Bhd from Teo Yek Ming, Ching Chee Pun, Lee Ching Yong and Low Chee Yeap for MYR 12.4 million.

New 90-day high: RM0.20

Is Sunzen Biotech Berhad (KLSE:SUNZEN) Weighed On By Its Debt Load?

Third quarter 2020 earnings released: RM0.001 loss per share

Sunzen Biotech Berhad Announces Re-Designation of Ching Chee Pun from Non-Independent Director to Executive Director

First half earnings released

New 90-day high - RM0.21

Rendimenti per gli azionisti

Volatilità dei prezzi

Informazioni sull'azienda

Sunzen Biotech Berhad Riepilogo dei fondamenti

40.8x

2.6x

Guadagni e ricavi